These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7508886)

  • 1. Association of p53 immunoreactivity with high gleason tumor grade in prostatic adenocarcinoma.
    Kallakury BV; Figge J; Ross JS; Fisher HA; Figge HL; Jennings TA
    Hum Pathol; 1994 Jan; 25(1):92-7. PubMed ID: 7508886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate carcinoma.
    Petrescu A; Mârzan L; Codreanu O; Niculescu L
    Rom J Morphol Embryol; 2006; 47(2):143-6. PubMed ID: 17106522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study.
    Sasor A; Wagrowska-Danilewicz M; Danilewicz M
    Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
    Tamboli P; Amin MB; Xu HJ; Linden MD
    Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma.
    Iczkowski KA; Pantazis CG; McGregor DH; Wu Y; Tawfik OW
    Cancer; 2002 Dec; 95(12):2487-93. PubMed ID: 12467061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 immunoreactivity in primary and metastatic prostatic adenocarcinoma.
    Hughes JH; Cohen MB; Robinson RA
    Mod Pathol; 1995 Jun; 8(5):462-6. PubMed ID: 7675761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.
    Pierconti F; Martini M; Cenci T; Petrone GL; Ricci R; Sacco E; Bassi PF; Larocca LM
    Prostate; 2017 May; 77(6):597-603. PubMed ID: 28144985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8 kb major breakpoint region or with p53 protein accumulation.
    Kallakury BV; Figge J; Leibovich B; Hwang J; Rifkin M; Kaufman R; Figge HL; Nazeer T; Ross JS
    Mod Pathol; 1996 Jan; 9(1):41-7. PubMed ID: 8821955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between apoptosis regulator proteins (bcl-2 and p53) and Gleason score in prostate cancer.
    Karaburun Paker S; Kilicarslan B; Ciftcioglu AM; Oztekin S; Sargin FC; Erdogru T; Baykara M
    Pathol Oncol Res; 2001; 7(3):209-12. PubMed ID: 11692148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.
    Zhao J; Epstein JI
    Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 and p21/WAF-1 overexpressions in prostatic adenocarcinoma.
    Wan Muhaizan WM; Ahmad PK; Phang KS; Arni T
    Malays J Pathol; 2006 Dec; 28(2):93-9. PubMed ID: 18376798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear p53 overexpression in bladder, prostate, and renal carcinomas.
    Sinik Z; Alkibay T; Ataoglu O; Biri H; Sözen S; Deniz N; Karaoglan U; Bozkirli I
    Int J Urol; 1997 Nov; 4(6):546-51. PubMed ID: 9477181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 34betaE12 and P63 in 100 consecutive prostate carcinoma diagnosed by needle biopsies.
    Wu HH; Lapkus O; Corbin M
    Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):285-9. PubMed ID: 15536326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate.
    Zeng L; Rowland RG; Lele SM; Kyprianou N
    Hum Pathol; 2004 Mar; 35(3):290-7. PubMed ID: 15017584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between histological type and immunohistochemical profile of prostate cancer and gleason scale gradation.
    Iemelynova AA; Grygorenko VM; Cheremuha SV; Romanenko AM
    Exp Oncol; 2009 Dec; 31(4):246-9. PubMed ID: 20010526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells.
    De Marzo AM; Meeker AK; Epstein JI; Coffey DS
    Am J Pathol; 1998 Sep; 153(3):911-9. PubMed ID: 9736039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia.
    Jack GS; Brash AR; Olson SJ; Manning S; Coffey CS; Smith JA; Shappell SB
    Hum Pathol; 2000 Sep; 31(9):1146-54. PubMed ID: 11014584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence of surfactant protein A and D expression decrement and their localizations in human prostate adenocarcinomas.
    Kankavi O; Baykara M; Eren Karanis MI; Bassorgun CI; Ergin H; Ciftcioglu MA
    Ren Fail; 2014 Mar; 36(2):258-65. PubMed ID: 24168624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate.
    Arora R; Koch MO; Eble JN; Ulbright TM; Li L; Cheng L
    Cancer; 2004 Jun; 100(11):2362-6. PubMed ID: 15160339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of p53 and expression of CD44 in human prostatic cancer and benign prostatic hyperplasia: an immunohistochemical study.
    Zhang XH; Sakamoto H; Takenaka I
    Br J Urol; 1996 Mar; 77(3):441-4. PubMed ID: 8814853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.